申请人:YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.
公开号:EP0776892A1
公开(公告)日:1997-06-04
Thienylazole compounds (I) and thienotriazolodiazepine compounds (II) of the formulas
wherein R1 and R2 are hydrogen, halogen, C1-C5 alkyl and the like; -A=B-is -N=N- and the like; R3 and R19 are hydrogen, C1-C5 alkyl and the like; Y is -NHCO, -NHCONH-, -NHCOO- and the like; Z1 and Z2 are aryl, heteroaryl and the like; Ar is halogen-substituted phenyl and the like; and m is 0 or an integer of 1-5.
The compounds of the present invention have CCK antagonistic action and gastrin antagonistic action, particularly potent antagonistic action against CCK-A receptor, and are useful as agents for the prophylaxis and treatment of central and peripheral nervous system diseases (e.g., anxiety, schizophrenia, and the like) and digestive diseases (e.g., pancreatitis, gastric ulcer, enterelcosis, irritable bowel syndrome, constipation, and the like).
噻吩基氮唑化合物(I)和噻吩三唑并二氮杂卓化合物(II),其式如下
其中 R1 和 R2 是氢、卤素、C1-C5 烷基和类似物;-A=B- 是-N=N- 和类似物;R3 和 R19 是氢、C1-C5 烷基和类似物;Y 是-NHCO、-NHCONH-、-NHCOO- 和类似物;Z1 和 Z2 是芳基、杂芳基和类似物;Ar 是卤素取代的苯基和类似物;m 是 0 或 1-5 的整数。
本发明的化合物具有 CCK 拮抗作用和胃泌素拮抗作用,特别是对 CCK-A 受体具有强效的拮抗作用,可作为预防和治疗中枢和周围神经系统疾病(如焦虑症、精神分裂症等)和消化系统疾病(如胰腺炎、胃溃疡、肠梗阻、肠易激综合征、便秘等)的药物。